Robert Shorr

Learn More
CPI-613 is a novel anti-tumor compound with a mechanism-of-action which appears distinct from the current classes of anti-cancer agents used in the clinic. CPI-613 demonstrates both in vitro and in(More)
Paclitaxel is an important anticancer drug and is currently used to treat a variety of cancers, including ovarian carcinomas, breast cancer, non-small cell lung cancer, and AIDS-related Kaposi's(More)
STUDY RATIONALE AND OBJECTIVES Via genetic alterations, malignant transformation and proliferation are associated with extensive alterations of mitochondrial energy metabolism of tumor cells. Thus,(More)
CRANBURY, NJ, September 15, 2011– Cornerstone Pharmaceuticals, Inc., (http://www.cornerstonepharma.com), a leader in cancer metabolism-based therapeutics, today announced the publication of data from(More)
  • 1